Epigral targets 20% annual growth, more than double revenue by FY28

Q: How long will it take to read this news story?

The story "Epigral targets 20% annual growth, more than double revenue by FY28" has 511 words across 18 sentences, which will take approximately 3 - 5 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Epigral targets 20% annual growth, more than double revenue by FY28" was covered 10 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 151 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #26330563</li><li>URL: https://beamstart.com/news/epigral-targets-20-annual-growth-17402218662799</li></ul>

Business Standard Logo Business Standard 10h ago

Epigral targets 20% annual growth, more than double revenue by FY28 - Business Standard

Quick Summary:

Epigral reported a little over 37 per cent jump in consolidated revenue to Rs 1,934.31 crore in the first nine months of 2024-25 compared to Rs 1,409.55 crore in the year-ago period, according to exchange filings.

Specialty chemicals major Epigral Ltd aims to grow at an annual growth rate of 20 per cent and is poised to more than double its revenue by FY2028, a top company official said on Saturday.

Sustained demand for derivative and specialty products as well as doubling of production capacity will act as key catalysts for the overall revenue growth, Epigral's Chairman and Managing Director, Maulik Patel said in a statement.